Imaging tumor lactate is feasible for identifying intermediate- risk prostate cancer patients with postsurgical biochemical recurrence
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA(2023)
摘要
While radical prostatectomy remains the mainstay of prostate cancer (PCa) treatment, 20 to 40% of patients develop postsurgical biochemical recurrence (BCR). A particularly challenging clinical cohort includes patients with intermediate -risk disease whose risk stratification would benefit from advanced approaches that complement standard -of -care diagnostic tools. Here, we show that imaging tumor lactate using hyperpolarized 13C MRI and spatial metabolomics identifies BCR- positive patients in two prospective intermediate -risk surgical cohorts. Supported by spatially resolved tissue analysis of estab-lished glycolytic biomarkers, this study provides the rationale for multicenter trials of tumor metabolic imaging as an auxiliary tool to support PCa treatment decision- making.
更多查看译文
关键词
prostate cancer,cancer metabolism,MRI
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要